Regulatory Role of OX22\textsuperscript{high} T Cells in Mercury-induced Autoimmunity in the Brown Norway Rat

By Peter W. Mathieson, Sathia Thiru,\textsuperscript{*} and David B. G. Oliveira

From the Departments of Medicine and \textsuperscript{*}Pathology, University of Cambridge, Cambridge CB2 2SP, UK

Summary
The monoclonal antibody OX22 defines a functional split within CD4\textsuperscript{+} T cells in the rat, with OX22\textsuperscript{high} cells mainly producing interleukin 2 (IL-2) and interferon \gamma and responsible for delayed-type hypersensitivity responses, and OX22\textsuperscript{low} cells mainly producing IL-4 and IL-5 and responsible for providing B cell help. There are reciprocal interactions between OX22\textsuperscript{high} and OX22\textsuperscript{low} cells, and it has been suggested that the OX22\textsuperscript{low} subset has a role in the prevention of autoimmunity. We have used OX22 in vivo to define the role of these subsets in mercuric chloride-induced autoimmunity in the Brown Norway rat. In this model, there is polyclonal B cell activation and animals develop widespread tissue injury. Treatment of thymectomized animals with OX22 led to a profound reduction in the number of OX22\textsuperscript{high} T cells in the peripheral blood. OX22-treated animals consistently developed more severe tissue injury than controls given an irrelevant antibody of the same isotype. Control animals pretreated with broad spectrum antimicrobial drugs showed milder tissue injury, but this protective effect of antimicrobials was lost in OX22-treated animals. Transfer of naive T cells to OX22-treated animals provided protection, but if T cells were depleted in vitro of OX22\textsuperscript{high} cells before transfer, this effect was lost. These data provide evidence for a protective immunoregulatory role for OX22\textsuperscript{high} T cells in mercuric chloride-induced autoimmunity.

The functional split of T cells defined by the cell-surface markers CD4 and CD8 is well-known, with helper/inducer T cells defined by expression of CD4 and suppressor/cytotoxic T cells defined by CD8. There has been considerable recent progress in the characterization of functionally distinct T cell subpopulations within these major categories. In the mouse, CD4\textsuperscript{+} cells can usually be subdivided on the basis of the cytokines they secrete, with one subset (Th1) predominantly producing IL-2 and IFN-\gamma, and a second subset (Th2) predominantly producing IL-4 and IL-5 and responsible for providing B cell help (1). There is evidence of a similar functional split within CD4\textsuperscript{+} T cells in the rat (2, 3) and in humans (4). A number of phenotypic markers have been used to define subsets of CD4\textsuperscript{+} T cells, and one of the best studied of these is the CD45 molecule, also known as the leukocyte common antigen (5–7). CD45 occurs in several different isoforms that are derived by differential splicing of at least three variable exons situated near the 5' end of the gene (8). A number of mAbs are available that recognize specific CD45 isoforms denoted CD45RO, CD45RA, CD45RB, and CD45RC (9). In the rat, the mAb MRC-OX22 binds to a high molecular weight isoform (CD45RB and/or CD45RC) and defines subpopulations of CD4\textsuperscript{+} T cells with different functions (2, 10). OX22\textsuperscript{high} CD4\textsuperscript{+} cells produce IL-2 and IFN-\gamma, but little IL-4, whereas OX22\textsuperscript{low} CD4\textsuperscript{+} cells provide B cell help, producing more IL-4 with less IL-2 and IFN-\gamma (2, 10). Transfer of OX22\textsuperscript{high} CD4\textsuperscript{+} T cells into nude athymic rats has been reported to induce a severe wasting disease with inflammation in a number of organs, whereas transfer of OX22\textsuperscript{low} CD4\textsuperscript{+} T cells has no such effect (11). Furthermore, if unfractionated CD4\textsuperscript{+} T cells were transferred, i.e., containing a mixture of approximately two-thirds OX22\textsuperscript{high} and one-third OX22\textsuperscript{low}, the nude recipients remained well, indicating that there is an interaction between the two subsets, with the OX22\textsuperscript{low} population apparently able to inhibit the deleterious effect of the OX22\textsuperscript{high} cells (11).

Mercuric chloride (HgCl\textsubscript{2}) is a T cell–dependent polyclonal B cell activator that induces autoimmunity in susceptible rodent strains. In the Brown Norway (BN) rat, HgCl\textsubscript{2} induces a self-limiting autoimmune syndrome with autoreactive CD4\textsuperscript{+} T cells (12, 13), hypergammaglobulinemia predominantly affecting the IgE class (14), and a number of IgG autoantibodies including antibodies to glomerular basement membrane (GBM) (15). We have recently reported (16) that HgCl\textsubscript{2}-treated BN rats develop widespread tissue injury, par-

Abbreviations used in this paper: BN, Brown Norway; GBM, glomerular basement membrane.
particularly affecting the gut, skin, and liver, with some features resembling GVHD. We have examined the effect of OX-22 treatment in vivo on the autoimmune response induced in BN rats by HgCl₂. Our results provide evidence for a protective regulatory role of OX22⁺ T cells in this experimental model.

Materials and Methods

Experimental Model. BN rats were obtained from OLAC (Bicester, UK) and a breeding colony established. For all experiments, animals were used in age- and sex-matched groups. Rats were given HgCl₂ diluted in distilled water by five subcutaneous injections over a 7-d period, each injection consisting of 1 mg/kg HgCl₂. Animals were weighed regularly and serial blood samples were taken from a tail vein for analysis of lymphocyte subsets (heparinized blood) and for separation of serum for assay of anti-GBM antibodies. Where antimicrobial pretreatment was used, animals were given tylosin (Tylan®, Eli Lilly Italia, Florence, Italy) 10 mg/kg per day subcutaneously for 4 d, metronidazole (Toryg®, May & Baker, Dagenham, UK) 20 mg/kg per day subcutaneously for 5 d, and ivemectin (Ivomec®, Merck, Sharp & Dohme, Hoddesdon, Herts, UK) 200 µg/kg subcutaneously on the first and fifth days. For the in vivo mAb treatment, animals were given mAbs by daily intravenous injection for 5 d immediately before starting HgCl₂.

Anti-GBM Antibody Assay. Sera were assessed for anti-GBM antibody by a solid phase RIA as described previously (17). Briefly, a collagenase digest of normal rat glomeruli was coated onto microtiter plates (Dynatech Laboratories, Inc., Chantilly, VA). After washing, the plates were incubated with test or control sera and bound antibody detected with goat anti-rat IgG (Sigma Immunochemicals, Poole, Dorset, UK) radiolabeled with ³¹¹I by the chloramine T method. Sera were assayed in triplicate and the mean result expressed as a percentage of a strongly positive reference serum.

In Vivo mAb Treatment. Thymectomies were performed at age 3–4 wk by suction via a partial sternotomy wound under ether anesthesia. Animals were allowed to recover for at least 2 wk and then given mAbs 200 µg daily for five consecutive days by intravenous injection via a tail vein. The mAbs were produced in tissue culture medium containing 1% BSA (British Drug House, Poole, Dorset, UK), Hypaque (Pharmacia, Milton Keynes, UK). All dilutions were in PBS containing 1% BSA, and sera were dialyzed into PBS and filter sterilized. Test animals were divided into three groups, with nine rats given OX22, nine given OX8, and nine given no mAb (controls). In the second experiment (n = 27), nine rats received OX22, nine received OX8, and nine received an irrelevant mAb (20), and five animals were given no mAb. In the second experiment (n = 27), nine rats received OX22, nine received OX8, and nine received A5, an irrelevant mAb of the same isotype (21). These experiments were designed to analyze the effect of these mAbs on the immunoregulation of the autoantibody response (20), and so detailed histological analysis was not carried out on all animals. However, the external appearances of the animals were scored according to an arbitrary scale: 0, normal; 1, mild; 2, mild to moderate; 3, moderate to severe; and 4, severe. These scores were then added up to give a total tissue injury score for each animal, with a possible maximum score of 12.

Results

Experimental Design. The results are reported of four experiments involving a total of 96 animals (summarized in Fig. 1). In the first experiment (n = 15), five rats received OX22, five received OX8 to deplete CD8⁺ T cells (20), and five received no mAb. In the second experiment (n = 27), nine rats received OX22, nine received OX8, and nine received A5, an irrelevant mAb of the same isotype (21). These experiments were designed to analyze the effect of these mAbs on the immunoregulation of the autoantibody response (20), and so detailed histological analysis was not carried out on all animals. However, the external appearances of the animals were scored according to an arbitrary scale to assess the severity of the mucocutaneous inflammation, and in experiment 2, histology was obtained from nine of the animals (three in each group). Taking experiments 1 and 2 together, there was a significant difference between the groups in terms of external scores (p = 0.04, Kruskal-Wallis analysis of variance), with the OX22 group having more severe inflammation and the OX8 group not being significantly different from controls. The histological analysis of nine animals in experiment 2 showed that the OX22-treated animals had more severe tissue injury than the controls (p < 0.05) and the OX8 group (p < 0.05). The controls and the OX8 group were not significantly different.
**Figure 1.** Experimental design.

**Figure 2.** Flow cytometry analysis. (A) PBLs from untreated animal, stained with OX22 (LFL1). (B) PBLs from OX22-treated animal, stained with OX22 (LFL1). (C) Nylon wool-separated T cells, stained with OX22 (LFL1). (D) T cells after in vitro depletion of OX22 high cells, stained with OX22 (LFL1).
Having observed that OX22 treatment exacerbated tissue injury, we designed the third and fourth experiments to confirm and extend this observation. In the third experiment \((n = 18)\), nine animals were pretreated with antimicrobials and nine were not. In each group of nine, five received OX22 and four received control mAb. In the fourth experiment \((n = 36)\), 30 animals were pretreated with antimicrobials and six were not. In the pretreated group, six received control mAb and 24 received OX22. The OX22-treated animals were further subdivided into three groups of eight for the cell transfers: eight received unfractionated T cells, eight received OX22-depleted T cells, and eight received no cell transfer.

**Flow Cytometry Analysis.** PBLs from untreated animals gave a typical profile of staining with OX22, with two peaks of positive-staining cells, designated OX22\(^{\text{high}}\) and OX22\(^{\text{low}}\), typically accounting for 55–65% and 30–40% of total PBLs, respectively (Fig. 2 A). Using double staining, there was a population of OX22\(^{\text{high}}\) T cells which accounted for 35–45% of total PBLs (data not shown). Animals receiving control mAb showed no difference from untreated animals. OX22-treated animals showed loss of the OX22\(^{\text{high}}\) peak (Fig. 2 B) and reduction of the double-staining OX22\(^{\text{high}}\) T cells to 10% or less of the total. Flow cytometric analysis of the spleen cells used in the cell transfers showed that 96–97% of the nylon wool-separated cells were OX52 positive, i.e., a relatively pure population of T cells. This cell preparation contained OX22\(^{\text{high}}\) and OX22\(^{\text{low}}\) cells (Fig. 2 C), and after in vitro depletion with OX22, the OX22\(^{\text{high}}\) population had been removed (Fig. 2 D).

**Tissue Injury: External Appearances.** As we have reported previously (16), rats developed severe inflammation of mucocutaneous junctions by 10–12 d after HgCl\(_2\). In the two initial experiments in which various anti-T cell mAbs were used, it was a consistent observation that the external inflammation was most marked in animals that had received OX22. As also reported previously (16), antimicrobial pretreatment greatly reduced the severity of the mucocutaneous inflammation, but this was less apparent in the OX22-treated animals, in which the protective effect of antimicrobials was overcome by the exacerbating effect of OX22 treatment.

**Tissue Injury: Body Weight.** In the fourth experiment, animals were weighed sequentially. Animals not pretreated with antimicrobials showed significant weight loss compared with pretreated animals \((p = 0.002)\), with a mean weight loss of 5.9% of baseline body weight in the nonpretreated group compared with a mean weight gain of 2.4% of baseline in the pretreated animals. There was a trend to greater weight loss in the OX22-treated animals than in the controls, but this did not quite reach statistical significance \((p = 0.06)\).

**Tissue Injury: Histology.** In the third and fourth experiments, the differences between the tissue injury seen in the various groups were quantified using the histological scoring system. In the third experiment, OX22-treated animals had more severe tissue injury than controls \((p <0.0005, \text{Fig. 3})\). There was no significant protective effect of antimicrobial pretreatment in this experiment (data not shown). Fig. 4 shows the effect of OX22 treatment and antimicrobial treatment in experiment 4. OX22-treated animals had more severe tissue injury than animals receiving control mAb (Fig. 4, first bar compared with third bar at each time point, \(p <0.005\)). Within the groups of animals receiving control mAb, antimicrobial pretreated animals had milder tissue injury than animals not pretreated (Fig. 4, first bar compared with second bar, \(p = 0.039\)). Animals pretreated with antimicrobials and then given OX22 were not significantly different from animals not pretreated with antimicrobials (Fig. 4, second bar com-
pared with third bar, \( p = 0.32 \)), indicating that OX22 treatment overcame the protective effect of antimicrobial pretreatment. Fig. 5 shows histological data for the cell transfer recipients: animals receiving unfractionated T cells had milder tissue injury than animals receiving \( T \) cells depleted in vitro of OX22\(^{\text{high}} \) cells (\( p = 0.007 \)).

**Anti-GBM Antibody Titers.** In none of the experiments was there any significant difference in anti-GBM titer between OX22-treated animals and controls (Fig. 6). As reported previously (16), antimicrobial pretreatment did not affect anti-GBM titer.

**Discussion**

From this series of experiments, we conclude the following: treatment of thymectomized rats with OX22 in vivo leads to loss of OX22\(^{\text{high}} \) T cells. Animals treated with OX22 before receiving HgCl\(_2\) develop more severe tissue injury than animals receiving a control mAb, and the protective effect of antimicrobial pretreatment in this experimental model is overcome by OX22 administration. OX22 treatment does not affect anti-GBM autoantibody levels. Transfer of unfractionated T cells from naive animals to OX22-treated animals reduces the severity of tissue injury, but transfer of \( T \) cells depleted of OX22\(^{\text{high}} \) cells confers less protection. Taken together, these data provide evidence for the hypothesis that OX22\(^{\text{high}} \) T cells play a protective immunoregulatory role in mercuric chloride-induced autoimmunity.

The epitope recognized by OX22 is found on macrophages and B cells as well as T cells (10, 22). This widespread distribution might have been expected to decrease the chances of administered OX22 antibody affecting a particular T cell subset. However, our data clearly demonstrate the loss of OX22\(^{\text{high}} \) staining T cells. We cannot be sure whether this represents depletion of the OX22\(^{\text{high}} \) T cell subset or simply modulation of the OX22 target from the cell surface. The distinction between these possibilities is not critical since a number of in vitro studies have shown that antibodies directed against various CD45 epitopes can have functional effects in the absence of cell killing (23–27). Our data show functional effects of OX22 in vivo, irrespective of the precise fate of the OX22\(^{\text{high}} \) T cell subset. Since CD8\(^+ \) T cells are also OX22\(^{\text{high}} \), treatment with OX22 in vivo would be expected to affect these cells, as well as the OX22\(^{\text{high}} \) subset of CD4\(^+ \) T cells. The data from experiments 1 and 2 indicate that OX8 treatment in vivo, which effectively depletes CD8\(^+ \) T cells (20), does not worsen tissue injury. We have conducted numerous experiments in which CD8\(^+ \) T cells were depleted (20), and we have never observed any exacerbation of tissue injury as a result of this treatment. Indeed, in many cases, OX8-treated animals seemed to have less severe tissue injury (our unpublished observations). Depletion of CD8\(^+ \) T cells by OX22 treatment cannot therefore explain our observations, and by implication, the effects of OX22 treatment in vivo are likely to be due to depletion of OX22\(^{\text{high}} \) CD4\(^+ \) T cells.

In the experiments alluded to earlier (11), it was the OX22\(^{\text{high}} \) subset of T cells that led to tissue injury in nude rats, and the OX22\(^{\text{low}} \) subset which were protective. This has led to the suggestion (2) that OX22\(^{\text{low}} \) CD4\(^+ \) T cells play a role in the prevention of autoimmunity in vivo. Our data on HgCl\(_2\)-induced autoimmunity indicate that in this model the roles of these subsets are reversed, with the OX22\(^{\text{low}} \) subset having a deleterious effect and the OX22\(^{\text{high}} \) subset playing a protective role. It has been postulated that HgCl\(_2\)-induced autoimmunity reflects preferential activation of Th2-type CD4\(^+ \) T cells, since there is polyclonal B cell activation and hyper-IgE (28). In the mouse, IL-4 (predominantly a Th2 product) is a key cytokine in HgCl\(_2\)-induced autoimmunity (28, 29). In the rat, IL-4 is mainly produced by the OX22\(^{\text{low}} \) subset of T cells (2). Since it is known that
there are reciprocal interactions between \( \text{OX22}^{\text{high}} \) and \( \text{OX22}^{\text{low}} \) T cells (11), if \( \text{HgCl}_2 \) preferentially activates \( \text{OX22}^{\text{low}} \) (i.e., Th2-type) cells, it is perhaps not surprising that depletion of \( \text{OX22}^{\text{high}} \) (i.e., Th1-type) cells should lead to exacerbation of tissue injury in this model. There is evidence that the respective roles of \( \text{OX22}^{\text{high}} \) and \( \text{OX22}^{\text{low}} \) cells in alloimmune reactions are more akin to the roles we postulate in \( \text{HgCl}_2 \)-induced autoimmunity, with the \( \text{OX22}^{\text{high}} \) subset having a "suppressor" role (30) and the \( \text{OX22}^{\text{low}} \) subset being effector cells (31). The protective effect of \( \text{OX22}^{\text{high}} \) cells which we observed may be strain specific. BN rats have anomalous T cell subsets, with a small CD8\(^+\) population (20), and a high ratio of \( \text{OX22}^{\text{low}} \) to \( \text{OX22}^{\text{high}} \) CD4\(^+\) T cells compared with other strains.

Genetic factors play an important part in determining the response to \( \text{HgCl}_2 \). In the rat, MHC and background genes are both involved in determining the response to \( \text{HgCl}_2 \) (32-34). The MHC haplotype that confers susceptibility is RT-1\(^{a}\) (32). In resistant strains of rat, \( \text{HgCl}_2 \) induces immunosuppression, such as induction of organ-specific autoimmunity, e.g., experimental allergic encephalomyelitis (35) or Heymann nephritis (36), in rat strains which are normally fully susceptible, is prevented by prior treatment to immune diseases, e.g., experimental allergic encephalomyelitis (32-34). The MHC haplotype that confers susceptibility is RT-1\(^{a}\) (32). In resistant strains of rat, \( \text{HgCl}_2 \) induces immunosuppression, such as induction of organ-specific autoimmunity, e.g., experimental allergic encephalomyelitis (35) or Heymann nephritis (36), in rat strains which are normally fully susceptible, is prevented by prior treatment to immune diseases, e.g., experimental allergic encephalomyelitis (32-34). The MHC haplotype that confers susceptibility is RT-1\(^{a}\) (32). In resistant strains of rat, \( \text{HgCl}_2 \) induces immunosuppression, such as induction of organ-specific autoimmunity, e.g., experimental allergic encephalomyelitis (35) or Heymann nephritis (36), in rat strains which are normally fully susceptible, is prevented by prior treatment to immune diseases, e.g., experimental allergic encephalomyelitis (32-34). The MHC haplotype that confers susceptibility is RT-1\(^{a}\) (32). In resistant strains of rat, \( \text{HgCl}_2 \) induces immunosuppression, such as induction of organ-specific autoimmunity, e.g., experimental allergic encephalomyelitis (35) or Heymann nephritis (36), in rat strains which are normally fully susceptible, is prevented by prior treatment.

The effector mechanisms mediating tissue injury in this model are not well-defined. A direct pathogenic role for autoantibodies seems unlikely since in our experiments autoantibody titers were not affected by \( \text{OX22} \) treatment or antimicrobials, so that there was a dissociation between severity of tissue injury and level of autoantibody. A role for granulocytes is suggested by the infiltration of tissues by these cells and the development of a leucocytoclastic vasculitis (16). \( \text{OX22}^{\text{low}} \) cells have a particular propensity to recruit cells of the granulocyte lineage (40), so this could provide one mechanism for the deleterious role of \( \text{OX22}^{\text{low}} \) cells. As indicated earlier, depletion of CD8\(^+\) T cells in vivo may be associated with a protective effect, indicating that CD8\(^+\) T cells may play a role as effectors. Alternatively, the tissue injury may be directly mediated by \( \text{OX22}^{\text{low}} \) T cells. Although it is known that \( \text{OX22}^{\text{high}} \) T cells mediate some forms of GVHD (10), there is evidence that in so-called "syngeneic" GVHD, the key effector cell has an \( \text{OX22}^{\text{low}} \) phenotype (41, 42). The tissue injury we observed has some similarities with GVHD (16), and since our animals had not received a graft, the model may more closely resemble syngeneic GVHD, which is thought to be autoimmune mediated (43).

The protective effect of antimicrobial pretreatment is also of interest. The severity of tissue inflammation in GVHD is influenced by microbial load, both in experimental animals (44) and in humans (45), with pathogen-free individuals developing much less severe disease. Furthermore, in human diseases characterized by necrotizing leucocytoclastic vasculitis similar to that seen in our animals, antibiotics alone may have useful therapeutic effects (46), and tissue injury is known to be exacerbated by intercurrent infection (47). One possible mechanism for an effect of infection is illustrated by the recent demonstration that infection with a nematode can break T cell tolerance, apparently preferentially affecting the IL-4-producing (Th2-type) subset (48). In our experience, the protective effect of antimicrobials is somewhat variable. For instance, in the experiments described here, the effect was seen in the fourth experiment but not in the third. This may simply reflect variation in the microbial load of different batches of animals. Antimicrobials would not be expected to have any effect if the pathogen load of the animals is low.

\( \text{HgCl}_2 \)-induced autoimmunity in the BN rat has features in common with a number of human autoimmune diseases (summarized in reference 49). At present, the treatment of human autoimmunity usually involves the use of nonspecific immunosuppressive drugs. If certain lymphocyte subsets have deleterious roles and others are protective, therapy could be improved by using reagents such as mAbs to specifically target the damaging subset. At present, little is known about the role of subsets of CD4\(^+\) T cells in humans, but this is an area where further advances could lead to the design of more specific forms of immunotherapy for human disease.

In summary, we have presented evidence that tissue injury in BN rats with \( \text{HgCl}_2 \)-induced autoimmunity is exacerbated by in vivo depletion of \( \text{OX22}^{\text{high}} \) T cells, and that restoration of this population by cell transfer provides protection. Thus, \( \text{OX22}^{\text{high}} \) T cells seem to play an important protective immunoregulatory role in this model. This finding has implications for the understanding of interactions between Th1- and Th2-type cells in the rat, and may also have relevance to human autoimmunity.
We would like to thank Margaret McLeish for technical assistance with the histological studies.

Peter W. Mathieson is a Medical Research Council Clinician Scientist Fellow and David B. G. Oliveira is a Lister Institute Research Fellow.

Address correspondence to Dr. P. W. Mathieson, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2SP, UK.

Received for publication 7 October 1992 and in revised form 28 January 1993.

References

1. Mosmann, T.R., and R.L. Coffman. 1989. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 46:111.

2. McKnight, A.J., A.N. Barclay, and D.W. Mason. 1991. Molecular cloning of rat interleukin 4 cDNA and analysis of the cytokine repertoire of subsets of CD4+ T cells. Eur. J. Immunol. 21:1187.

3. Papp, I., K.J. Wieder, T. Sablinski, P.J. O'Connell, E.L. Millican, D.W. Mason, A.F. Williams, and G.P. Spickett. 1992. Evidence for functional heterogeneity of rat CD4+ T cells in vivo. J. Immunol. 148:1308.

4. Salgame, P., J.S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R.L. Modlin, and B.R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science (Wash. DC). 254:279.

5. Hirohata, S., and P.E. Lipsky. 1989. T cell regulation of human B cell proliferation and differentiation. Regulatory influences of CD45R+ and CD45R- T4 cell subsets. J. Immunol. 142:2597.

6. Beverley, P.C.L. 1987. Human T cell subsets. Immunol. Lett. 14:263.

7. Smith, S.H., M.H. Brown, D. Rowe, R.E. Callard, and P.C.L. Beverley. 1986. Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1. Immunology. 53:63.

8. Thomas, M.L. 1989. The leukocyte common antigen family. Annu. Rev. Immunol. 7:339.

9. Schwinzer, R. 1989. Cluster report: CD45/CD45R. In Leukocyte Typing IV. White Cell Differentiation Antigens. W. Knapp, B. Drrken, W.R. Gilks, E.P. Rieber, R.E. Schmidt, H. Stein, and A.E.G. Kr. von dem Borne, editors. Oxford University Press, Oxford. 628.

10. Spickett, G.P., M.R. Brandon, D.W. Mason, A.F. Williams, and G.R. Woolett. 1983. MRC OX-22, a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte common antigen. J. Exp. Med. 158:795.

11. Powrie, F., and D. Mason. 1990. OX-22 high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22 low subset. J. Exp. Med. 172:1701.

12. Pelletier, L., R. Pasquier, F. Hirsch, C. Sapin, and P. Druet. 1986. Autoreactive T cells in mercury-induced autoimmune disease: in vitro demonstration. J. Immunol. 137:2548.

13. Rossert, J., L. Pelletier, R. Pasquier, and P. Druet. 1988. Autoreactive T cells in memory-induced autoimmunity. Demonstration by limiting dilution analysis. Eur. J. Immunol. 18:1761.

14. Prouvoest-Donon, A., A. Abadie, C. Sapin, H. Bazin, and P. Druet. 1981. Induction of IgE synthesis and potentiation of anti-ovalbumin IgE antibody response by HgCl2 in the rat. J. Immunol. 126:699.

15. Pusey, C.D., C. Bowman, A. Morgan, A.P. Weetman, B. Hartley, and C.M. Lockwood. 1990. Kinetics and pathogenicity of autoantibodies induced by mercuric chloride in the Brown Norway rat. Clin. Exp. Immunol. 81:76.

16. Mathieson, P.W., S. Thiru, and D.B.G. Oliveira. 1992. Mercuric chloride-treated Brown Norway rats develop widespread tissue injury including necrotizing vasculitis. Lab Invest. 67:121.

17. Bowman, C., D.K. Peters, and C.M. Lockwood. 1983. Antiglomerular basement membrane autoantibodies in the Brown Norway rat: detection by a solid-phase radioimmunoassay. J. Immunol. Methods. 61:325.

18. Robinson, A.P., M. Puklavac, and D.W. Mason. 1986. MRC OX-52: a rat T-cell antigen. Immunology. 57:527.

19. Siegel, S., and N.J. Castellan, Jr. 1988. Two independent samples. In Nonparametric Statistics for the Behavioural Sciences McGraw Hill, Singapore. 102.

20. Mathieson, P.W., K.J. Stapleton, D.B.G. Oliveira, and C.M. Lockwood. 1991. Immunoregulation of mercuri chloride-induced autoimmunity in Brown Norway rats: a role for CD8+ T cells revealed by in vivo depletion studies. Eur. J. Immunol. 21:2105.

21. Wedderburn, L., M.L. Lukic, S. Edwards, M.C. Kahan, N. Nardi, and N.A. Mitchison. 1984. Single-step immunosorbtion preparation of F-protein from mouse liver with conservation of the allo-antigenic site, and determination of concentration in liver and serum. Mol. Immunol. 21:979.

22. Arthur, R.P., and D. Mason. 1986. T cells that help B cells responses to soluble antigen are distinguishable from those producing interleukin 2 on mitogenic or allogenic stimulation. J. Exp. Med. 163:774.

23. Newman, W., L.D. Fast, and L.M. Rose. 1983. Blockade of NK cell lysis is a property of mononuclear antibodies that bind to distinct regions of T-200. J. Immunol. 131:1742.

24. Harp, J.A., B.S. Davis, and S.J. Ewald. 1984. Inhibition of T cell responses to alloantigens and polyclonal mitogens by Ly-5 antisera. J. Immunol. 133:10.

25. Takeuchi, T., S.F. Schlossman, and C. Morimoto. 1987. Induction of suppression following autologous mixed lymphocyte reaction: role of a novel 2H4 antigen. Eur. J. Immunol. 17:97.

26. Tighe, H., M. Clark, and H. Waldmann. 1987. Blocking of cytotoxic T cell function by monoclonal antibodies against the CD45 antigen (T200/leukocyte-common antigen). Transplantation (Baltimore). 44:818.

27. Bernabeu, C., A.C. Carrera, M.O. de-Landazuri, and F. Sanchez-Madrid. 1987. Interaction between the CD45 antigen
and phytohemagglutinin. Inhibitory effect on the lectin-induced T cell proliferation by anti-CD45 monoclonal antibody. *Eur. J. Immunol.* 17:1461.

28. Goldman, M., P. Druet, and E. Gleichmann. 1991. Th2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically-induced autoimmunity. *Immunol. Today.* 12:223.

29. Ochel, M., H.W Vohr, C. Pfeiffer, and E. Gleichmann. 1991. IL4 is required for the IgE and IgG1 increase and IgG1 autoantibody formation in mice treated with mercuric chloride. *J. Immunol.* 146:3006.

30. Hall, B.M., N.W. Pearce, K.E. Gurley, and S.E. Dorsch. 1990. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporin. III. Further characterization of the CD4⁺ suppressor cell and its mechanism of action. *J. Exp. Med.* 171:141.

31. Bradley, J.A., E.M. Bolton, J.D. Briggs, and J.A. Grade. 1989. Ability of a CD4⁺-positive, MRC OX22 “low” T-cell subpopulation to initiate renal allograft rejection in the athymic nude rat. *Transplant. Proc.* 21:326.

32. Druet, E., C. Sapin, G. Fournie, C. Mandet, E. Gunther, and P. Druet. 1977. Mercuric chloride-induced anti-glomerular basement membrane antibodies in the rat. Genetic control. *Eur. J. Immunol.* 7:348.

33. Druet, E., C. Sapin, G. Fournie, C. Mandet, E. Gunther, and F. Druet. 1982. Genetic control of susceptibility to mercury-induced immune nephritis in various strains of rat. *Clin. Immunol. Immunopathol.* 25:203.

34. Pelleter, L., J. Rossert, R. Pasquier, H. Villarroya, M.F. Belair, M.C. Vial, R. Oriol, and P. Druet. 1988. Effect of HgCl₂ on experimental allergic encephalomyelitis in Lewis rats. *HgCl₂*-induced down-modulation of the disease. *Eur. J. Immunol.* 18:243.

35. Mizrachi, J., C. Pfeiffer, J.A. Bruijn, F. Jaquesmart, and E. Gleichmann. 1989. Immunological alterations inducible by mercury compounds III. H-2A acts as an immune response and H-2E as an immune “suppression” locus for HgCl₂-induced antinucleolar autoantibodies. *Eur. J. Immunol.* 19:2257.

36. Pelleter, L., M. Galceran, R. Pasquier, P. Ronco, P. Verrout, J. Bariety, and P.H. Druet. 1987. Down modulation of Heymann’s nephritis by mercuric chloride. *Kidney Int.* 31:227.

37. Aten, J., A. Veninga, E. de Heer, J. Rozing, P. Nieuwenhuis, P.J. Hoedemaker, and J.J. Weening. 1991. Susceptibility to the induction of either autoimmunity or immunosuppression by mercuric chloride is related to the major histocompatibility complex class II haplotype. *Eur. J. Immunol.* 21:611.

38. Mizuno, K., S. Tsuchimoto, Y. Matsuno, T. Niyyama, H. Fujii, T. Natori, and M. Aizawa. 1988. The functional link between immune suppression gene and MHC class II molecules. *Immunogenetics.* 27:406.

39. Rivero, V.E., M.E. Ferro, M. Romero-Piffiguer, S. Correa, N. Yranzo-Volonté, and C.M. Riera. 1991. Antigen-induced inhibition of autoimmune response to rat male accessory glands: distinct characteristics of I-A⁻ and I-E⁺-positive peritoneal cells. *Eur. J. Immunol.* 21:1141.

40. Wang, C.H., M. Koenenaga, A. Greenwood, and R.G. Bell. 1990. T-helper subset function in the gut of rats: differential stimulation of eosinophils, mucosal mast cells and antibody-forming cells by OX8⁻ OX22⁻ and OX8⁺ OX22⁺ cells. *Immunology.* 71:166.

41. Fischer, A.C., M.K. Laulis, L. Horwitz, W.E. Beschorner, and A. Hess. 1989. Host resistance to cyclosporine induced syngeneic graft-versus-host disease: requirement for two distinct lymphocyte subsets. *J. Immunol.* 143:827.

42. Hess, A.D., A.C. Fischer, and W.E. Beschorner. 1990. Effector mechanisms in cyclosporine A-induced syngeneic graft versus host disease. Role of CD4⁺ and CD8⁺ T lymphocyte subsets. *J. Immunol.* 145:526.

43. Hess, A.D., L. Horwitz, W.E. Beschorner, and G.W. Santos. 1985. Development of graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. *J. Exp. Med.* 161:718.

44. Vossen, J.M., and P.J. Heidt. 1990. Gnotobiotic measures for the prevention of acute graft-vs.-host disease. *In Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment.* S.J. Burakoff, H.J. Deeg, J. Ferrara, and K. Atkinson, editors. Marcel Dekker, Inc., New York. 403.

45. Storb, R., R.L. Prentice, C.D. Buckner, R.A. Clift, F. Appelbaum, J. Deeg, K. Doney, J.A. Hansen, M. Mason, J.E. Sanders, et al. 1983. Graft-versus-host disease and survival in patients with aplastic anaemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. *N. Engl. J. Med.* 308:302.

46. Derene, R.A. 1989. The treatment of Wegener’s granulomatosis with trimethoprim-sulfamethoxazole: illusion or vision? *Arthritis Rheum.* 31:1068.

47. Pinching, A.J., A.J. Rees, B.A. Russell, C.M. Lockwood, R.S. Mitchison, and D.K. Peters. 1980. Relapses in Wegener’s granulomatosis: the role of infection. *Br. Med. J.* 281:836.

48. Röcken, M., J.F. Urban, and E.M. Shervach. 1992. Infection breaks T-cell tolerance. *Science (Wash. DC).* 359:79.

49. Mathieson, PW. 1992. Mercuric chloride-induced autoimmunity. *Autoimmunity.* 13:243.